Tempest Therapeutics, Inc.

NasdaqCM:TPST Stock Report

Market Cap: US$41.4m

Tempest Therapeutics Management

Management criteria checks 2/4

Tempest Therapeutics' CEO is Steve Brady, appointed in Jun 2021, has a tenure of 3.58 years. total yearly compensation is $7.01M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $44.02K. The average tenure of the management team and the board of directors is 3.5 years and 3.6 years respectively.

Key information

Steve Brady

Chief executive officer

US$7.0m

Total compensation

CEO salary percentage8.1%
CEO tenure3.6yrs
CEO ownership0.1%
Management average tenure3.5yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

CEO Compensation Analysis

How has Steve Brady's remuneration changed compared to Tempest Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$32m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$7mUS$567k

-US$29m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$530k

-US$36m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$715kUS$475k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$896kUS$461k

-US$19m

Compensation vs Market: Steve's total compensation ($USD7.01M) is above average for companies of similar size in the US market ($USD642.40K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Brady (54 yo)

3.6yrs

Tenure

US$7,007,407

Compensation

Mr. Stephen R. Brady, also known as Steve, LL M., J.D. served as an Independent Director at Atreca, Inc. since July 2021. He has been Chief Executive Officer & Director at Tempest Therapeutics Inc. since J...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director3.6yrsUS$7.01m0.11%
$ 44.0k
Nicholas Maestas
VP of Strategy & Finance and Secretary3.5yrsUS$1.32m0.020%
$ 8.2k
Samuel Whiting
Executive VP & Chief Medical Officer4.2yrsUS$3.38m0.022%
$ 9.1k
Justin Trojanowski
Corporate Controller2.3yrsno data0.051%
$ 21.0k
Lindsay Young
Head of Human Resourcesless than a yearno datano data

3.5yrs

Average Tenure

49yo

Average Age

Experienced Management: TPST's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director3.6yrsUS$7.01m0.11%
$ 44.0k
Christine Pellizzari
Independent Director3.5yrsUS$67.34k0%
$ 0
Michael Raab
Independent Chairman5.7yrsUS$107.84k0%
$ 0
Geoffrey Nichol
Independent Director3.6yrsUS$65.12k0%
$ 0
Andrew Pardoll
Member of Advisory Boardno datano datano data
Raymond DuBois
Member of Advisory Boardno datano datano data
Petpiboon Prasit
Member of Advisory Boardno datano datano data
Benjamin Cravatt
Member of Advisory Board5.7yrsno datano data
Ronit Simantov
Independent Director3.4yrsUS$57.62k0%
$ 0
Jason J. Luke
Member of Advisory Boardno datano datano data
Toni Choueiri
Member of Advisory Boardno datano datano data
Russell Vance
Member of Advisory Board3.3yrsno datano data

3.6yrs

Average Tenure

59yo

Average Age

Experienced Board: TPST's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 21:37
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tempest Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC
Aydin HuseynovLadenburg Thalmann & Company